Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Current Deferred Revenue (2021 - 2025)

Aligos Therapeutics' Current Deferred Revenue history spans 4 years, with the latest figure at $168000.0 for Q3 2025.

  • For Q3 2025, Current Deferred Revenue changed N/A year-over-year to $168000.0; the TTM value through Sep 2025 reached $168000.0, changed N/A, while the annual FY2024 figure was $151000.0, 88.46% down from the prior year.
  • Current Deferred Revenue reached $168000.0 in Q3 2025 per ALGS's latest filing, down from $579000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $7.6 million in Q1 2021 to a low of $151000.0 in Q4 2024.
  • Average Current Deferred Revenue over 4 years is $3.3 million, with a median of $1.3 million recorded in 2023.
  • The largest YoY upside for Current Deferred Revenue was 88.46% in 2024 against a maximum downside of 88.46% in 2024.
  • A 4-year view of Current Deferred Revenue shows it stood at $6.6 million in 2021, then plummeted by 80.29% to $1.3 million in 2023, then tumbled by 88.46% to $151000.0 in 2024, then grew by 11.26% to $168000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Current Deferred Revenue are $168000.0 (Q3 2025), $579000.0 (Q2 2025), and $151000.0 (Q4 2024).